Publications by authors named "E Wallenburg"
Background And Objectives: Although dose optimization studies have been performed for piperacillin and tazobactam separately, a combined integral analysis is not yet reported. As piperacillin and tazobactam pharmacokinetics are likely to show correlation, a combined pharmacokinetic model should be preferred to account for this correlation when predicting the exposure. Therefore, the aim of this study was to describe the pharmacokinetics and evaluate different dosing regimens of piperacillin and tazobactam in critically ill patients using an integral population pharmacokinetic model in plasma and urine.
View Article and Find Full Text PDFOral Antibiotics in Patients with Short Bowel Syndrome: Do or Don't?
Eur J Drug Metab Pharmacokinet
November 2021
High unbound flucloxacillin fraction in critically ill patients.
J Antimicrob Chemother
November 2021
Objectives: To describe the unbound and total flucloxacillin pharmacokinetics in critically ill patients and to define optimal dosing strategies.
Patients And Methods: Observational multicentre study including a total of 33 adult ICU patients receiving flucloxacillin, given as intermittent or continuous infusion. Pharmacokinetic sampling was performed on two occasions on two different days.
Article Synopsis
- The study aimed to create a model that accurately predicts unbound flucloxacillin concentrations in various patient groups.
- Researchers used non-linear mixed-effects modeling on data from healthy individuals and both non-critically and critically ill patients, totaling 710 paired concentration readings.
- Results showed the mechanistic model provided better predictions compared to a fixed unbound fraction of 5%, resulting in more accurate dosing recommendations for flucloxacillin, although both methods had limitations.